Αποτελέσματα Αναζήτησης
1 Απρ 2020 · Cancer immunotherapy is an innovative treatment for tumors today. In various experiments and clinical studies, it has been found that immunotherapy does have incomparable advantages over traditional anti-tumor therapy, which can prolong progression-free survival (PFS) and overall survival (OS).
- Conditioning Neoadjuvant Therapies for Improved Immunotherapy of Cancer
Rescovitine is not toxic for tumor-reactive T cells [79] and...
- Sci
Infectious complications, predominantly pulmonary and...
- Natural Killer Cells Unleashed
Cancer cells are cells undergoing unregulated cell division....
- Conditioning Neoadjuvant Therapies for Improved Immunotherapy of Cancer
1 Απρ 2020 · In this review article, we highlight the current standards of care in cancer immunotherapy, with a strong focus on immune checkpoint inhibitors (ici s), their limitations and pitfalls, and promising novel approaches.
This review gives an overview of recent developments in immunotherapy and indicates a new direction of tumor treatment through analyzing the pros and cons of immunotherapy coupled with keeping a close watch on the development trend of the immunotherapy future.
Immunotherapy undeniably plays an important part in cancer treatment—contributing to a future that transforms cancer from an acute diagnosis to a chronic manageable disease. But no anticancer treatment comes without risk.
17 Αυγ 2022 · Immunotherapy helps a person’s immune system to target tumor cells. Recent advances in cancer immunotherapy, including immune checkpoint inhibition, chimeric antigen receptor T-cell therapy and cancer vaccination, have changed the landscape of cancer treatment.
7 Απρ 2022 · Preclinical and clinical evidence have delivered the rationale for PD-1/PD-L1blockade as a millstone in cancer immunotherapy, rendering that induction of the PD-1/PD-L1 axis is respected as an efficient tool for tumor escape host tumor antigen-specific T-cell immunity.
20 Μαΐ 2024 · Immunotherapy in cancer treatment includes various treatment modalities. These include oncolytic virus therapy, cytokine therapies, adoptive immunotherapy, Chimeric Antigen Receptor (CAR) T-cell Therapy, antibodies, immune checkpoint inhibitors and cancer vaccines.
